BofA raised the firm’s price target on Johnson & Johnson (JNJ) to $161 from $159 and keeps a Neutral rating on the shares following the company’s “slight” topline beat in Q1 and EPS coming in 7% ahead of consensus. J&J also made small FY25 guidance updates for Intra-Cellular (ITCI) acquisition and foreign exchange impacts, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $159 from $158 at Bernstein
- Hold Rating for Johnson & Johnson Amid Mixed Outlook and Macroeconomic Challenges
- Johnson & Johnson: Balancing Stability and Risks Amid Tariff Challenges
- Cautious Outlook on Johnson & Johnson’s Orthopedic Segment Amid Slowed Growth and Competitive Pressure
- Johnson & Johnson Stock: Fairly Valued with Neutral Outlook Amid Uncertain Growth Prospects